Malaria vaccine MSP1/QS-21 - Antigenics

Drug Profile

Malaria vaccine MSP1/QS-21 - Antigenics

Alternative Names: MSP1/QS-21

Latest Information Update: 25 Sep 2006

Price : $50

At a glance

  • Originator Antigenics
  • Developer Antigenics; University of Hawaii
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Falciparum malaria

Most Recent Events

  • 24 Sep 2006 Discontinued - Preclinical for Falciparum malaria in USA (unspecified route)
  • 12 Dec 2003 No development reported - Preclinical for Falciparum malaria in USA (unspecified route)
  • 27 Aug 2001 Aquila Biopharmaceuticals has been integrated into Antigenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top